EMERYVILLE, Calif., March 26, 2025--(BUSINESS WIRE)--Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization (CRDMO) with a next generation RNA precision ...

Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company’s Board ...

She currently serves as Executive Chair and interim CEO of Nutcracker Therapeutics, a contract, research, development and manufacturing organization with a next generation RNA precision ...

Collins, 66, currently serves as Executive Chair and Interim Chief Executive Officer of Nutcracker Therapeutics, Inc. since February 2025. Her previous roles include CEO positions at Editas Medicine ...

Collins, 66, currently serves as Executive Chair and Interim Chief Executive Officer of Nutcracker Therapeutics, Inc. since February 2025. Her previous roles include CEO positions at Editas ...

EMERYVILLE, CA, USA I March 26, 2025 I Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization (CRDMO) with a next generation RNA precision manufacturing ...

Board of directors member, Cynthia Collins, will serve as executive chair Dr. Khandros will remain on the board of Nutcracker Therapeutics EMERYVILLE, Calif.--(BUSINESS WIRE)--Nutcracker Therapeutics, ...